{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"353.03","value":"744.0"},{"groupId":"OG001","spread":"303.38","value":"758.2"},{"groupId":"OG002","spread":"1378.53","value":"1363.0"},{"groupId":"OG003","spread":"538.94","value":"1010.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants received eribulin mesylate 1.1 mg/m\\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 4 cycles, or until PD or unacceptable toxicity or DLT's.","id":"OG000","title":"Part A1: Eribulin Mesylate 1.1 mg/m^2"},{"description":"Participants received eribulin mesylate 1.4 mg/m\\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 8 cycles, or until PD or unacceptable toxicity or drug related DLT's.","id":"OG001","title":"Part A1: Eribulin Mesylate 1.4 mg/m^2"},{"description":"Participants received eribulin mesylate 1.8 mg/m\\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 5 cycles, or until PD or unacceptable toxicity or drug related DLT's.","id":"OG002","title":"Part A1: Eribulin Mesylate 1.8 mg/m^2"},{"description":"Participants received eribulin mesylate 1.4 mg/m\\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 2 cycles, or until PD or unacceptable toxicity or drug related DLT's for evaluation of PK.","id":"OG003","title":"Part A1: Eribulin Mesylate PK Expansion"}],"paramType":"MEAN","populationDescription":"The PAS included all participants who had sufficient PK data to derive at least one PK parameter.","reportingStatus":"POSTED","timeFrame":"Day 1 predose and at 10, 30 minutes, 1, 2, 4, 6, 24, 48, 72, 96 or 120 hours post-dose","title":"AUC 0-t: Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration for Eribulin Mesylate","type":"PRIMARY","unitOfMeasure":"hour * nanogram per milliliter (h*ng/mL)"}